Use of aspirin in reduction of mortality of COVID‐19 patients: A meta‐analysis

Srivastava, Ritika; Kumar, Anoop

COVID‐19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID‐19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID‐19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID‐19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID‐19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle–Ottawa scale. The fixed‐effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID‐19 patients in aspirin group as compared with non‐aspirin group. However, no effect 0.00 [−0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.